Association of Peripheral CD4+ CXCR5+ T Cells with Chronic Lymphocytic Leukemia
Overview
Authors
Affiliations
Accumulating evidences indicate that immune dysregulation plays a key role in both lymphomagenesis and patient outcome of chronic lymphocytic leukemia (CLL). Peripheral blood CD4+ CXCR5+ T cells, known as circulating follicular helper T cells (Tfh), can induce B cell activation and production of specific antibody responses. The aim of the study was to investigate changes of circulating Tfh in CLL. Tfh and it subtypes were tested by measuring CD4, CXCR5, CXCR3, and CCR6 in 72 CLL cases and 86 healthy controls using flow cytometry. Data showed that the percentage of Tfh in the peripheral CD4+ T cells was significantly increased in CLL (25.1%) than in controls (8.4%) (p < 0.001). Further analysis revealed that the upregulation of Tfh was contributed by Tfh-th2 subtype and Tfh-th17 subtype. Investigating staging of the cases demonstrated that the prevalence of Tfh was significantly elevated in cases with Binet stage C (37.3%) than those with stage A (20.1 %) or stage B (23.9 %). In addition, we analyzed Tfh in patients with immunoglobulin variable heavy chain (IGHV) gene mutational status. Results presented that Tfh-th17 subtype had clearly higher frequency in patients with IGHV mutation compared to the unmutated cases (p = 0.035). This study suggested the involvement of Tfh in the pathogenesis and progression of CLL, and provided a potential target for treating this disease.
Rodrigues C, Laranjeira P, Pinho A, Silva I, Silva S, Coucelo M Front Oncol. 2024; 14:1380648.
PMID: 38606091 PMC: 11007165. DOI: 10.3389/fonc.2024.1380648.
Pfannes R, Pierzchalski A, Maddalon A, Simion A, Zouboulis C, Behre G Front Immunol. 2023; 14:1087996.
PMID: 37187728 PMC: 10177659. DOI: 10.3389/fimmu.2023.1087996.
Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy.
Andreu-Sanz D, Kobold S Cancers (Basel). 2023; 15(6).
PMID: 36980536 PMC: 10046829. DOI: 10.3390/cancers15061650.
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?.
Gamal W, Sahakian E, Pinilla-Ibarz J Blood Adv. 2022; 7(11):2401-2417.
PMID: 36574293 PMC: 10238851. DOI: 10.1182/bloodadvances.2022008985.
TIM-3 in Leukemia; Immune Response and Beyond.
Rezaei M, Tan J, Zeng C, Li Y, Ganjalikhani-Hakemi M Front Oncol. 2021; 11:753677.
PMID: 34660319 PMC: 8514831. DOI: 10.3389/fonc.2021.753677.